These findings establish that ITGα8 deletion provides functional benefits without increasing the risk of adverse cardiac events, suggesting that targeting ITGα8 represents a safe therapeutic approach for improving post‐MI outcomes. Here, ITGA8 is linked to myocardial infarction.